Song Yiqing, Stampfer Meir J, Liu Simin
Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts 02215, USA.
Ann Intern Med. 2004 Jul 20;141(2):137-47. doi: 10.7326/0003-4819-141-2-200407200-00013.
Apolipoprotein E (apoE) genotypes play critical roles in lipid metabolism and are believed to influence risk for coronary heart disease (CHD). Despite many population studies, however, the impact of apoE polymorphism on risk for CHD remains uncertain.
To qualitatively and quantitatively assess the evidence regarding the relation of apoE polymorphism to CHD risk.
All relevant reports and references from original and review papers published from 1966 to January 2004.
Predefined criteria were used to identify 48 relevant studies.
A summary database that contained variables of study design, study sample and ethnicity, sex, apoE genotypes, CHD end points, plasma lipid levels, and other CHD risk factors was developed.
The authors qualitatively evaluated many potential sources of heterogeneity. To quantify the extent of heterogeneity and assess the consistency of apoE-CHD associations, stratified analyses were conducted using the classic random-effects model. To further incorporate uncertainty due to between-study variation, the pooled odds ratios (ORs) and 95% credible intervals (CrIs) were estimated by using a Bayesian hierarchical model. Finally, the robustness of the pooled estimates was tested in multiple sensitivity analyses. Compared with individuals with the epsilon3/3 genotype, carriers of the apoE epsilon4 allele had a 42% higher risk for CHD (OR, 1.42 [95% CrI, 1.26 to 1.61]). The epsilon2 allele had no significant association with CHD risk (OR, 0.98 [CrI, 0.66 to 1.46]).
This meta-analysis did not include unpublished data or studies published in languages other than English.
Inadequate statistical power, differences in geographic and ethnic background, allele frequency, sex, CHD phenotypes, study design, and potential gene-environment interactions may have contributed to the conflicting results of previous studies. The apoE epsilon4 allele is a significant risk factor for CHD.
载脂蛋白E(apoE)基因型在脂质代谢中起关键作用,被认为会影响冠心病(CHD)风险。然而,尽管有许多人群研究,但apoE多态性对CHD风险的影响仍不确定。
定性和定量评估有关apoE多态性与CHD风险关系的证据。
1966年至2004年1月发表的原创论文和综述论文中的所有相关报告及参考文献。
使用预定义标准确定48项相关研究。
建立了一个汇总数据库,其中包含研究设计、研究样本及种族、性别、apoE基因型、CHD终点、血脂水平和其他CHD风险因素等变量。
作者对许多潜在的异质性来源进行了定性评估。为了量化异质性程度并评估apoE与CHD关联的一致性,使用经典随机效应模型进行分层分析。为了进一步纳入研究间变异导致的不确定性,使用贝叶斯分层模型估计合并比值比(OR)和95%可信区间(CrI)。最后,在多项敏感性分析中检验合并估计值的稳健性。与ε3/3基因型个体相比,apoE ε4等位基因携带者患CHD的风险高42%(OR,1.42 [95% CrI,1.26至1.61])。ε2等位基因与CHD风险无显著关联(OR,0.98 [CrI,0.66至1.46])。
这项荟萃分析未纳入未发表的数据或非英文发表的研究。
统计效力不足、地理和种族背景差异、等位基因频率、性别、CHD表型、研究设计以及潜在的基因-环境相互作用可能导致了先前研究结果的冲突。apoE ε4等位基因是CHD的一个重要风险因素。